Literature DB >> 24768118

Primary lung adenocarcinoma with morule-like components: a unique histologic hallmark of aggressive behavior and EGFR mutation.

Koji Tsuta1, Mitsumasa Kawago2, Akihiko Yoshida2, Shigeki Sekine2, Hisao Asamura3, Koh Furuta2, Ryoji Kushima2.   

Abstract

BACKGROUND: Lung adenocarcinoma with morule-like components is an unusual variant of lung adenocarcinoma, comprising uniform, tightly packed spindle-shaped cells, which fill the lumen of the glandular structures of the carcinoma. The aim of the study was to outline the clinicopathologic features of this variant. PATIENTS AND METHODS: We examined a series of 904 surgically resected adenocarcinomas. We defined morule-like components as small buds of spindle-cell proliferation in the tumor lumen of the glandular structures of the carcinoma and calculated their proportion of total tumor mass. Targeted genotyping was performed for KRAS, EGFR, HER2, and BRAF. ALK rearrangements were analyzed immunohistochemically. Immunopositive cases were confirmed using RT-PCR and/or FISH.
RESULTS: We detected 17 cases of adenocarcinoma with morule-like components. This variant, representing only 1.9% was associated with unfavorable outcomes and a mutation in the EGFR. Histologic examination revealed adenocarcinoma with morule-like components accounting for 5-50% of tumors. Among the morule-like components, 10 (58.8%) of the 17 samples showed intracytoplasmic lumina formation containing eosinophilic mucinous material. The presence of micropapillary components in adenocarcinoma with morule-like components suggests that morule-like components could be merely excessive growth of the micropapillary pattern. However, our results indicated no statistical differences in the MIB-1 indices of the morule-like components and the adjacent tumor components or the micropapillary components. The univariate and multivariate analyses revealed a correlation between the presence of a morule-like components and an unfavorable outcome.
CONCLUSIONS: Our study clearly indicated that adenocarcinoma with morule-like components is distinct unfavorable prognostic and predictor for EGFR mutation.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Epidermal growth factor receptor mutation; Intracytoplasmic mucin; Lung adenocarcinoma; Micropapillary; Morule; Unfavorable outcome

Mesh:

Substances:

Year:  2014        PMID: 24768118     DOI: 10.1016/j.lungcan.2014.03.022

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  5 in total

1.  Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes.

Authors:  Yi-Ran Cai; Yu-Jie Dong; Hong-Bo Wu; Da-Ping Yu; Li-Juan Zhou; Dan Su; Li Zhang; Xue-Jing Chen
Journal:  Oncol Lett       Date:  2016-09-02       Impact factor: 2.967

2.  Transition between morule-like and solid components may occur in solid-predominant adenocarcinoma of the lung: report of 2 cases with EGFR and KRAS mutations.

Authors:  Shogo Tajima; Kenji Koda
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

3.  Clinicopathological, Radiological, and Molecular Features of Primary Lung Adenocarcinoma with Morule-Like Components.

Authors:  Li-Li Wang; Li Ding; Peng Zhao; Jing-Jing Guan; Xiao-Bin Ji; Xiao-Li Zhou; Shi-Hong Shao; Yu-Wei Zou; Wei-Wei Fu; Dong-Liang Lin
Journal:  Dis Markers       Date:  2021-06-12       Impact factor: 3.434

4.  [Advances of Pulmonary Adenocarcinoma with Micropapillary Pattern].

Authors:  Xiangyu Shi; Qingsong Pang; Gang Zhao; Lujun Zhao; Ping Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-11

5.  Morule-like features in pulmonary adenocarcinoma associated with epidermal growth factor receptor mutations: two case reports with targeted next-generation sequencing analysis.

Authors:  Yoo Jin Lee; Harim Oh; Eojin Kim; Bokyung Ahn; Jeong Hyeon Lee; Youngseok Lee; Yang Seok Chae; Chul Hwan Kim
Journal:  J Pathol Transl Med       Date:  2019-11-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.